Daily Bulletin

Men's Weekly

.

Bionomics Receives FDA Clearance of IND for Evaluation of BNC210 in a Phase 2 Social Anxiety Disorder PREVAIL Study

  • Written by PR Newswire Asia - Daily Bulletin Au RSS
  • U.S. FDA clearance of IND for BNC210 evaluation as an acute treatment for patients with Social Anxiety Disorder in a Phase 2 clinical trial, the PREVAIL Study
  • The PREVAIL Study remains on target to initiate by end of 2021 and is expected to read out topline data by end of 2022

ADELAIDE, Australia, Nov. 1, 2021 /PRNewswire/ -- Bionomics Limited...

Read more: Bionomics Receives FDA Clearance of IND for Evaluation of BNC210 in a Phase 2 Social Anxiety...

Business News

Strategic partnerships to enable global acceleration for Aussie fashion brands: SHEIN Xcelerator launches

SHEIN Xcelerator is introducing a more agile, demand-led operating model, allowing brands to scale while retaining control over creative direction and identity. For fashion brands, the pressure t...

Daily Bulletin - avatar Daily Bulletin

Tips for Avoiding Probate Delays

Probate can be a lengthy process at the best of times, and delays often compound the stress that comes with managing a loved one's estate. Many of those delays are avoidable with the right preparati...

Daily Bulletin - avatar Daily Bulletin

Integrating Marketing Automation Workflows with Headless CMS: Creating a Unified Engine for Scalable Growth

Marketing automation is a necessary component of modern engagement with customers. Automated emails, triggered campaigns, lead nurturing and lifecycle messaging enable brands to scale their messagin...

Daily Bulletin - avatar Daily Bulletin